Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial

Affiliations

• ¹ Department of Ophthalmology, Nihon University School of Medicine, 1-6 Surugadai, Kanda, Chiyodaku, Tokyo, 101-8309, Tokyo, Japan. mori.ryusaburo@nihon-u.ac.jp.
• ² Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
• ³ Department of Ophthalmology, Hyogo Medical University, Hyogo, Japan.
• ⁴ Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
• ⁵ Department of Ophthalmology, University of the Ryukyus, Okinawa, Japan.
• ⁶ Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
• ⁷ Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan.